A Study to Evaluate the Safety of Xolair in Moderate to Severe Persistent Asthma Patients (ALTO)

NCT00401596 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1899

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Xolair (omalizumab)

Sponsor

Genentech, Inc.